Table 1.
Modulation of P-gp expression by agents that induce astroglial reactivity.
| Treatment | Concentration | Effect |
| dBcAMP | 0,5 mM | - 3.1 ± 8 |
| IL-1β | 50 ng/ml | +10.5 ± 11 |
| Lesion | / | - 12.1 ± 8 |
| LPS | 1 μg/ml | + 2.3 ± 8 |
| NGF | 10 ng/ml | - 21.7 ± 22 |
| RA | 10-7 M | - 28.6 ± 20.2 |
| rhIFN-β | 600 U/ml | -20 ± 11 |
|
rhIFNγ rhTGFα |
300 U/ml 50 ng/ml |
+50 ± 30 -9 ± 5 |
| TNFα | 100 ng/ml | + 7.6 ± 9.1 |
| rhCT-1 | 10 ng/ml | + 69.6 ± 24** |
| rhLIF | 30 ng/ml | + 54.3 ± 12** |
| rmIL-6 | 40 ng/ml | +68.8 ± 10*** |
| RmIL-6 | 50 ng/ml | +220.28 ± 22*** |
| + | ||
| rhsIL-6R | 500 ng/ml | |
| rrCNTF | 250 ng/ml | + 75.7 ± 30* |
*: ANOVA significant at 95%, t-test p < 0.05; **: ANOVA significant at 95%, t-test p < 0.01; ***: ANOVA significant at 95%, t-test p < 0.001.